Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer

Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer

Submitted by admin on July 2, 2020 - 11:09am
Source: 
Pharmaceutical Business Review
News Tags: 
Daiichi Sankyo
antibody-drug conjugate
triple negative breast cancer
DS-1062
clinical trials
Headline: 
Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer
snippet: 

Daiichi Sankyo Company announced the first patient with triple negative breast cancer (TNBC) has been dosed in the ongoing phase 1 study assessing DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC).

Do Not Allow Advertisers to Use My Personal information